Literature DB >> 24399558

Pharmacological treatments for smoking cessation.

Kate Cahill1, Sarah Stevens2, Tim Lancaster1.   

Abstract

CLINICAL QUESTION: Among the 3 first-line smoking cessation treatments (nicotine replacement therapy [NRT], bupropion, and varenicline), which is most effective in helping people who smoke achieve and maintain abstinence from smoking for at least 6 months, and what serious adverse events are associated with each? BOTTOM LINE: Higher rates of smoking cessation were associated with NRT (17.6%) and bupropion (19.1%) compared with placebo (10.6%). Varenicline (27.6%) and combination NRT (31.5%) (eg, patch plus inhaler) were most effective for achieving smoking cessation. None of the therapies was associated with an increased rate of serious adverse events.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24399558     DOI: 10.1001/jama.2013.283787

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  63 in total

1.  Development of a Discrete Choice Experiment (DCE) Questionnaire to Understand Veterans' Preferences for Tobacco Treatment in Primary Care.

Authors:  David A Katz; Kenda R Stewart; Monica Paez; Mark W Vander Weg; Kathleen M Grant; Christine Hamlin; Gary Gaeth
Journal:  Patient       Date:  2018-12       Impact factor: 3.883

2.  Prevalence of cigarette smoking and attempts to quit in a population-based cohort with spinal cord injury.

Authors:  L L Saunders; J S Krause; M Saladin; M J Carpenter
Journal:  Spinal Cord       Date:  2015-04-28       Impact factor: 2.772

3.  Step Care treatment for smoking cessation.

Authors:  Jon O Ebbert; Melissa A Little; Robert C Klesges; Zoran Bursac; Karen C Johnson; Fridtjof Thomas; Mark W Vander Weg
Journal:  Health Educ Res       Date:  2017-02-01

4.  Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update.

Authors:  Sheldon W Tobe; James A Stone; Todd Anderson; Simon Bacon; Alice Y Y Cheng; Stella S Daskalopoulou; Justin A Ezekowitz; Jean C Gregoire; Gord Gubitz; Rahul Jain; Karim Keshavjee; Patty Lindsay; Mary L'Abbe; David C W Lau; Lawrence A Leiter; Eileen O'Meara; Glen J Pearson; Doreen M Rabi; Diana Sherifali; Peter Selby; Jack V Tu; Sean Wharton; Kimberly M Walker; Diane Hua-Stewart; Peter P Liu
Journal:  CMAJ       Date:  2018-10-09       Impact factor: 8.262

5.  Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction.

Authors:  Albert Garcia-Romeu; Roland R Griffiths; Matthew W Johnson
Journal:  Curr Drug Abuse Rev       Date:  2014

6.  Effects of varenicline versus transdermal nicotine replacement therapy on cigarette demand on quit day in individuals with substance use disorders.

Authors:  Cara M Murphy; James MacKillop; Rosemarie A Martin; Jennifer W Tidey; Suzanne M Colby; Damaris J Rohsenow
Journal:  Psychopharmacology (Berl)       Date:  2017-05-13       Impact factor: 4.530

Review 7.  Consideration of sex in clinical trials of transdermal nicotine patch: a systematic review.

Authors:  Andrea H Weinberger; Philip H Smith; Mira Kaufman; Sherry A McKee
Journal:  Exp Clin Psychopharmacol       Date:  2014-08-18       Impact factor: 3.157

8.  Administration of the nicotinic acetylcholine receptor agonists ABT-089 and ABT-107 attenuates the reinstatement of nicotine-seeking behavior in rats.

Authors:  Alycia M Lee; Adrian C Arreola; Blake A Kimmey; Heath D Schmidt
Journal:  Behav Brain Res       Date:  2014-08-14       Impact factor: 3.332

9.  Long-term follow-up of psilocybin-facilitated smoking cessation.

Authors:  Matthew W Johnson; Albert Garcia-Romeu; Roland R Griffiths
Journal:  Am J Drug Alcohol Abuse       Date:  2016-07-21       Impact factor: 3.829

10.  Culturally-Tailored Smoking Cessation for Adult American Indian Smokers: A Clinical Trial.

Authors:  Stevens S Smith; Leah M Rouse; Mark Caskey; Jodi Fossum; Rick Strickland; J Kevin Culhane; Jerry Waukau
Journal:  Couns Psychol       Date:  2014-07-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.